Nuwellis is a medical device company that operates in the healthcare industry. The company's main offering is the Aquadex SmartFlow® System, a therapy that gently removes excess fluid from the bodies of adult and pediatric patients suffering from fluid overload, providing an alternative to diuretics and other renal replacement technologies. Nuwellis primarily serves the healthcare sector, with a particular focus on heart failure, critical care, and pediatric fluid imbalance. It was founded in 1999 and is based in Eden Prairie, Minnesota.
Nuwellis has filed 44 patents.
Membrane technology, Kidney diseases, Renal dialysis, Nephrology, Nephrology procedures
Membrane technology, Kidney diseases, Renal dialysis, Nephrology, Nephrology procedures
Latest Nuwellis News
Feb 8, 2024
Credit: Neonatal Kidney Collaborative Our resilient kidneys are invaluable members of the body’s purification system, and they excel at bouncing back after injury. This even holds true for most sick infants in the neonatal intensive care unit. Because of this remarkable ability, dips in kidney function in infants were often overlooked historically in favor of other pressing diseases or symptoms. But physicians and researchers have shown increased interest in understanding kidney health in newborns and young infants within the last decade, leading to the AWAKEN study (Assessment of Worldwide Acute Kidney Epidemiology in Neonates). With initial results reported in 2017, AWAKEN was the first major multicenter effort to examine acute kidney injury, or AKI, in newborns. In a recently published follow-up analysis of the AWAKEN data in JAMA Network Open, Austin Rutledge, D.O. , a fellow in neonatal and perinatal medicine at the Medical University of South Carolina, led a multicenter team to examine the impact of repeat episodes of AKI in hospitalized infants. Their work was performed on behalf of the Neonatal Kidney Collaborative , a nonprofit group of neonatologists and pediatric nephrologists working to reduce the burden of kidney disease in newborns. The original AWAKEN study showed that 30% of the approximately 2,000 babies studied had an AKI and that having an AKI was associated with a fourfold higher risk of death. Heidi Steflik, M.D., MSCR , a neonatologist at MUSC and one of the primary investigators on the recent report, emphasized that the AWAKEN study revealed kidney disease as not only very common in newborns but also an independent contributor to infant mortality. That is, it is not just an ancillary result or an indicator of other illness. “But what we didn't know from the original data was if these babies had experienced one or multiple episodes of AKI,” added Rutledge. “So we didn’t know if the ones who had multiple AKIs had a greater chance of death or if one AKI was enough to adversely affect outcomes.” The research team reexamined the AWAKEN data to see if certain groups of infants were more prone to repeat episodes and if these repeat incidents increased the risk of death or other adverse outcomes. The MUSC researchers collaborated with Russell Griffin, Ph.D., a statistician at the University of Alabama at Birmingham, and with researchers from several other medical centers. They combed through the data by hand to determine which babies with AKI across 24 neonatal intensive care units nationwide had one or multiple occurrences, using newly defined criteria to make the call. They looked at characteristics like gestational age, birth weight and the initial stage of AKI, and they examined outcomes like risk of death and length of hospitalization. They discovered that a large proportion of babies with AKI had recurrences: of the 605 infants with AKI, 133 had more than one episode. But the mortality rate increased with any AKI, starting from the very first episode. “Because the kidneys tend to bounce back, AKI has sometimes been disregarded in the past,” said Steflik. “But we found that even one episode of AKI is dangerous.” Further episodes did not add an additional risk of death but were associated with lengthier hospital stays for these children, some of whom were in the NICU for months. Further, the long-term effects of these injuries are still under investigation. Similar results were found in a separate study of MUSC patients in 2020-2021. Based on these findings, Rutledge and Steflik suggest that both initial AKI and recurrent episodes deserve careful monitoring and management as well as further study. “Kidney health is something that has been underappreciated across the spectrum, but particularly in babies,” said Steflik. “We're really excited to be part of the groups that are paying attention.” Looking to the future, Rutledge explained that researchers are looking for better ways to detect and measure AKI, since the current measurement – the serum creatinine level – has a delay before showing positivity. There is also interest in learning more specifics about the duration of AKI as well as the long-term impacts on children. “As we continue to study the long-term effects of AKI, we want families and parents to understand how important it is to follow up with a nephrologist after a NICU stay,” said Rutledge. “Our goal is for every baby who has had kidney injury to be monitored regularly for kidney health.” Journal COI Statement Dr Askenazi reported receiving grant funding from Nuwellis Inc during the conduct of the study; consulting fees from Baxter International Inc, SeaStar Medical, Nuwellis Inc, Abbott Laboratories, and BioPorto A/S outside the submitted work; institutional grant funding from the National Institutes of Health (NIH), Baxter International Inc, Leadiant Biosciences, Nuwellis Inc, Medtronic PLC, BioPorto A/S, Portero, and SeaStar Medical; being the founder and chief scientific officer for Zorro-Flow Inc; and having patents pending for a female urine collection device and for improvements in continuous kidney replacement therapy. Dr Steflik reported grant funding from Baxter International Inc for continuous kidney replacement therapy–related research outside the submitted work. No other disclosures were reported. Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system. Media Contact
Nuwellis Frequently Asked Questions (FAQ)
When was Nuwellis founded?
Nuwellis was founded in 1999.
Where is Nuwellis's headquarters?
Nuwellis's headquarters is located at 12988 Valley View Road, Eden Prairie.
What is Nuwellis's latest funding round?
Nuwellis's latest funding round is IPO - II.
How much did Nuwellis raise?
Nuwellis raised a total of $32.3M.
Who are the investors of Nuwellis?
Investors of Nuwellis include Gambro, MPM Capital, Investor Growth Capital, Mason Wells, Brightstone Venture Capital and 6 more.
Who are Nuwellis's competitors?
Competitors of Nuwellis include Brain Tunnelgenix Technologies, SynCardia Systems, Sensible Medical Innovations, GlySure, Drew Scientific and 7 more.
Compare Nuwellis to Competitors
Nephrologix Inc. is a private company that develops, manufactures and markets peritoneal dialysis (PD) systems.
Sensible Medical Innovations is a company focused on healthcare technology. The company's main offering is a non-invasive system for monitoring and managing lung fluid levels in patients with heart failure and other chronic diseases requiring lung fluid level monitoring. The company primarily serves the healthcare industry. It was founded in 2007 and is based in Netanya, Israel.
SpineAlign Medical is an early-stage medical device company focused on developing minimally-invasive products for spine disorders. The company's main product is a nitinol implant designed to treat vertebral compression fractures, primarily affecting osteoporosis patients. SpineAlign Medical's technologies cater to the healthcare sector, with a focus on improving patient outcomes in spinal treatments. It is based in Pleasanton, California.
Cutera is a global aesthetics device company operating in the medical technology sector. The company offers a range of products and solutions for aesthetic treatments, including body sculpting, skin revitalization, hair removal, and tattoo removal. Cutera primarily serves the medical aesthetics industry. It was founded in 1998 and is based in Brisbane, California.
Atritech has developed the WATCHMAN, an implantable device designed to capture clots that may form in the left atrial appendage of patients with atrial fibrillation, thereby aiming to reduce the risk of stroke and eliminating the need for long-term use of blood thinning medications.
Biowatch Medical focuses on the development and manufacturing of ambulatory cardiac monitors within the healthcare technology sector. Their main products are FDA-approved cardiac monitoring devices available for both prescription and over-the-counter use, accompanied by round-the-clock monitoring services for patients and support for physicians. It was founded in 2001 and is based in Columbia, South Carolina.